Proteona releases ESCAPE™ RNA sequencing for measuring protein and RNA in single cells with a focus on clinical questions.
Innovative genomic and proteomic analysis platform for Immuno-Oncology and Single Cell BioMedical Applications
SINGAPORE, 10 December 2018 Proteona announced today the launch of their first commercial product line, ESCAPE™ RNA Sequencing for clinical ProteoGenomics. ESCAPE™ (Enhanced Single Cell Analysis with Protein Expression) is currently being offered globally as a service and an early adopter premium kit program is now open for enrollment.
ESCAPE™ RNA sequencing is the first commercial product line to enable researchers to simultaneously measure both gene and protein expression from the same single cells. Both the service and the kit make use of the 10x Genomics platform for making single cell RNA sequencing libraries, while Proteona provides pre-pooled and titrated DNA barcoded antibodies and associated reagents for producing protein expression sequencing libraries. Proteona also provides an analysis suite and bioinformatics services for helping researchers and clinicians make use of the large datasets produced by the assay.
“We are excited to begin offering this technology to the wider research and clinical community. Over the past two years we have worked hard to validate large sets of DNA barcoded antibodies that can be added to any single cell RNA sequencing experiment. The list of proteins we can measure grows every day and with each conversation we have with every new researcher from academia and industry. The best part is the limitless numbers of proteins we can measure per cell all without altering the RNA sequencing data generated by the 10x Genomics RNA sequencing assay. Our added bioinformatics support is key to helping our customers make new discoveries about their samples and move the data closer to making a clinical impact. It is truly a fantastic time to be doing biological research”
10x Genomics co-founder and CEO, Serge Saxonov agrees, "10x Genomics recently opened offices in Asia to service customers and forge new partnerships in the area. We are excited to be collaborating with Proteona to further work in immuno-oncology and cell therapy and look forward to more genomic applications coming out of Asia."
Global enquiries for Proteona’s ESCAPE™ RNA Sequencing services or questions about enrolment in the ESCAPE™ RNA Seq Kit early adopter program, email email@example.com
For media queries, please contact:
Dr Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).